Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU

A Phase I/II, Randomised, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU

The main purpose of the this study is to evaluate the safety and tolerability of Immunose™ FLU based on Endocine™ and quadrivalent influenza antigen.

Study Overview

• Status: Completed
• Conditions: Influenza, Human
• Intervention / Treatment: Biological: 15 µg HA/strain and 1% Endocine™; Biological: 15 µg HA/strain and 2% Endocine™; Biological: 15 µg HA/strain; Biological: Placebo, Saline; Biological: intramuscular comparator; Biological: intranasal comparator

• Study Type: Interventional
• Enrollment (Actual): 162
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Sweden
  • Linkoping, Sweden
    • Site 2
  • Uppsala, Sweden
    • Site 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 39 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Signed informed consent prior to any study related procedures.
• Male or female 18-39 years of age (both inclusive) at screening
• Subjects who the Investigator believes will comply with the requirements of the protocol.
• BMI: 18.0 and 30.0 kg/m2 (inclusive).
• Judged by the Investigator to have no serious illness based on medical history, physical examination, ECG, vital signs and blood and urine assessments at screening.
• From the signing of the informed consent until 2 months after the last vaccination (Visit 3 for group 1 to 4 and Visit 2 for group 5 and 6) female subjects have to use contraceptive methods with a failure rate of < 1% to prevent pregnancy (combined [oestrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen- only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD], intrauterine hormone-releasing system [IUS], bilateral tubal occlusion, sexual abstinence). Any male partner should be willing to use condom or should be vasectomized.

Exclusion Criteria:

• Diagnosis of laboratory-confirmed influenza in the 2015/2016 season.
• Use of any investigational drug product within 3 months before screening or planned use during the study period, including the safety follow-up.
• Administration of an influenza vaccine during the 6 months before screening.
• Previously received another vaccine within 28 days before administration of the study vaccine, or is scheduled to receive another vaccine during the study period, excluding the safety follow-up.
• Any contra-indication to intramuscular administration of the influenza vaccine AdimFlu-S according to its prescribing information.
• Any contra-indication to administration of the influenza vaccine Fluenz Tetra according to its summary of product characteristics (SmPC).
• History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g., to eggs or egg product as well as ovalbumin, chicken protein, chicken feathers, influenza viral protein, kanamycin, gentamycin and neomycin sulphate).
• Diagnosis of asthma with poor disease control as assessed by the Investigator.
• Potent immunosuppressive therapy including cytostatics, antibodies, drugs acting on immunophilins, interferons and other drugs used to prevent rejection of organ transplants, within 6 months before screening.
• Use of any parenteral or oral corticosteroids within 30 days prior to screening. Inhaled steroids are allowed.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
• Any progressive or severe neurologic disorder, seizure disorder or Guillain-Barré syndrome.
• History of Guillain-Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
• Received blood, blood products and/or plasma derivatives or any administration of immunoglobulin preparation within the three months prior to Visit 2, or planned during the study.
• Participation in blood donation within 3 months or plasma donation within 1 month prior to Visit 2.
• History of substance or alcohol abuse within the past 2 years.
• History or any illness/condition that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
• Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and HIV.
• Pregnant or lactating female or intent to become pregnant during the clinic phase (up until and including Visit 4 for group 1 to 4 and Visit 3 for group 5 and 6) and for 2 months after the last vaccination.
• History of Bell's palsy.
• Ongoing regular use of intranasal sprays including corticosteroids and decongestants.
• Ongoing cough, sinusitis, allergic rhinitis, nasal polyps or obstruction, including septum deviation significant enough to prevent bilateral administration of study vaccine.
• Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
• Subjects that are prone to nosebleed.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Immunose™ FLU 1%,; 15 µg haemagglutinin(HA)/strain and 1% Endocine™	Biological: 15 µg HA/strain and 1% Endocine™; intranasal administration
Experimental: Immunose™ FLU 2%,; 15 µg HA/strain and 2% Endocine™	Biological: 15 µg HA/strain and 2% Endocine™; intranasal administration
Experimental: Influenza antigen,; 15 µg HA/strain	Biological: 15 µg HA/strain; intranasal administration
Placebo Comparator: Saline (NaCl),; Placebo	Biological: Placebo, Saline; intranasal administration
Active Comparator: i.m. comparator,; 15 µg HA/strain	Biological: intramuscular comparator; intramuscular administration
Active Comparator: i.n. comparator	Biological: intranasal comparator; intranasal administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Local Tolerability - First Dose	Local tolerability, as measured by at least one of the administration site reactions swelling, redness, pain and pruritus, regardless of severity.	Pre-dose, and 15 and 120 min after study drug administration (Visit 2).
Local Tolerability - Second Dose (Group 1-4 Only)	Local tolerability, as measured by at least one of the administration site reactions swelling, redness, pain and pruritus, regardless of severity.	Pre-dose, and 15 and 120 min after second study drug administration (Visit 3).

Collaborators and Investigators

• Sponsor: Eurocine Vaccines AB
• Investigators: Principal Investigator: Cornelia Lif-Tiberg, MD, CTC

Study record dates

Study Major Dates

• Study Start: September 1, 2016
• Primary Completion (Actual): June 1, 2017
• Study Completion (Actual): June 1, 2017

Study Registration Dates

• First Submitted: November 10, 2016
• First Submitted That Met QC Criteria: December 16, 2016
• First Posted (Estimate): December 21, 2016

Study Record Updates

• Last Update Posted (Actual): February 21, 2019
• Last Update Submitted That Met QC Criteria: October 8, 2018
• Last Verified: October 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Orthomyxoviridae Infections; Influenza, Human; Physiological Effects of Drugs; Immunologic Factors; Adjuvants, Immunologic; Endocine
• Other Study ID Numbers: EURO 15-11

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO